Table 1.
Patient and disease characteristics at baseline
| 10 mg/kg GSK3052230 (n = 3) | 15 mg/kg GSK3052230 (n = 25) | 20 mg/kg GSK3052230 (n = 8) | Total (n = 36) | ||
|---|---|---|---|---|---|
| Sex, n (%) | |||||
| Female | 1 (33%) | 8 (32%) | 2 (25%) | 11 | (31%) |
| Male | 2 (67%) | 17 (68%) | 6 (75%) | 25 | (69%) |
| Age, mean (range), years | 72.3 | 57.1 | 70.9 | 61 | |
| [65–80] | [25–75] | [60–78] | [25–80] | ||
| Age group, n (%) | |||||
| 18–64 | 0 | 16(64%) | 1 (13%) | 17 | (47%) |
| 65–74 | 2 (67%) | 8 (32%) | 4 (50%) | 14 | (39%) |
| >74 | 1 (33%) | 1 (4%) | 3 (38%) | 5 | (14%) |
| ECOG PS, n (%) | |||||
| 0 | 1 (33%) | 17 (68%) | 5 (63%) | 23 | (64%) |
| 1 | 2 (67%) | 8 (32%) | 2 (25%) | 12 | (33%) |
| 2 | 0 | 0 | 1 (13%) | 1 | (3%) |
| Prior treatment, n (%) | |||||
| Surgery | 2 (67%) | 12 (48%) | 6 (75%) | 20 | (56%) |
| Chemotherapya | 0 | 1 (4%) | 0 | 1 | (3%) |
| Histology, n (%) | |||||
| Medullary | 0 | 10 (40%) | 2 (25%) | 12 | (33%) |
| Epithelioid | 2 (66%) | 4 (16%) | 0 | 6 | (16%) |
| Sarcomatoid | 0 | 3 (12%) | 1 (13%) | 4 | (11%) |
| Biphasic | 0 | 0 | 1 (13%) | 1 | (3%) |
| Otherb | 1 (33%) | 8 (32%) | 4 (50%) | 13 | (36%) |
| Ethnicity, n (%) | |||||
| White | 3 (100%) | 24 (96%) | 8 (100%) | 35 | (97%) |
| Asian | 0 | 1 (4%) | 0 | 1 | (3%) |
| Unknown | 0 | 0 | 0 | 0 |
ECOG PS, Eastern Cooperative Oncology performance status;
a
one patient received prior oxaliplatin/pemetrexed;
b
Histological subtype of 13 patients was not provided in the pathology report; however, their diagnosis of malignant pleural mesothelioma was confirmed histologically at screening, per protocol